Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-SWITCH: Immune changes after switching factor VIII products in hemophilia A
NL-OMON46126Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Factor VIII, recombinant human coagulation factor VIII and efmoroctocog alfa in hemophilia A (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in immunologic profile after switch. Started Sep 2017; status: active, not recruiting.
02
Drugs
Factor VIIIrecombinant human coagulation factor VIIIefmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON46126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46126.